Navigation Links
Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
Date:2/27/2008

llion, the majority of which are derived from the three largest markets; France, the United Kingdom and Germany.

Revenues from Asia Pacific were $170.9 million for the three months ended December 31, 2007 and were derived from Mylan's newly acquired operations in Australia, Japan and New Zealand.

For the Specialty Segment, total revenues for the three months ended December 31, 2007 were $102.1 million. The Specialty Segment consists of the Dey business that focuses on the development, manufacturing and marketing of specialty pharmaceuticals in the respiratory and severe allergy markets.

The Matrix Segment reported total revenues of $107.1 million, of which $92.9 million represents sales to third parties.

Gross profit for the three months ended December 31, 2007 was $356.1 million and gross margins were 30.8%. The decrease in gross margins is due primarily to the effects of purchase accounting items recorded during the quarter of approximately $117.7 million, which consisted primarily of amortization related to purchased intangible assets and the amortization of the inventory step-up associated with the acquisition of Merck Generics. Excluding such items, gross margins were 41.0% compared to 55.9% for the three months ended December 31, 2006.

The Company reported a loss from operations of $1.27 billion for the three months ended December 31, 2007. This loss from operations for the quarter included a $1.27 billion one-time charge to write-off acquired in-process research and development, which is recorded without a tax effect, and excludes the $117.7 million of purchase accounting items discussed above. Excluding these amounts, earnings from operations would have been $118.5 million, a decrease of $65.1 million from the prior year.

Research and development ("R&D") expense for the three months ended December 31, 2007 was $80.8 million compared to $22.9 million in the same prior year period. R&D expense includes approximately $5
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
2. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
3. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
4. Mylan Restores Availability of Generic Levothyroxine in Florida
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
8. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
9. Mylan Sets Date of 2008 Annual Meeting
10. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
11. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... North Central Surgical Center is proud to announce ... top-notch services. The hospital was the recipient for several ... , Hospital-wide, North Central was the recipient of the ... award for two years in a row (2013-2014). They ... nation for Patient Safety in 2014 and ranked among ...
(Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of ... to develop the disease at lower body weights? One ... from traditional high-fiber, low-fat Asian diets to current westernized ... Asian heritage, says George King, M.D., Senior Vice President ... the senior author of the study. , A Joslin ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... explain the increased cases , FRIDAY, Nov. 6 (HealthDay News) ... people at higher risk of getting a type of thyroid ... related to cancer, but researchers suspect that the toxic compounds ... also unsure of why thyroid cancer rates are rising around ...
... a sneeze, people worry more about flu, heart attacks, accidents and ... may sound hard to believe, but just one sneeze is enough ... of dying from a heart attack at an early age, dying ... new research shows. , Of greater concern, however, was that people ...
... Nov. 6 HeartWare International, Inc. (Nasdaq: ... provider of less invasive, miniaturized circulatory support technologies revolutionizing ... it is scheduled to make presentations at two upcoming ... be made at the Third Annual Canaccord Adams Cardiovascular ...
... ... Award. , ... LA (PRWEB) November 6, 2009 -- Gilsbar, a national leader in health benefit ... was recently honored with Platinum-Level recognition for the American Heart Association Start! Fit-Friendly Companies ...
... ... and the recently released World Alzheimer Report declares that more than 35 million people ... innovator with 16 independent living and assisted living, and Alzheimer,s/memory care communities in Wisconsin ... of Alzheimer,s disease. , ...
... Tobacco-Free Kids, American Cancer Society, American Cancer Society Cancer ... American Legacy Foundation , WASHINGTON, Nov. 5 ... judge in Kentucky today rejected a motion by tobacco ... giving the U.S. Food and Drug Administration (FDA) the ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:Health Fears Are Nothing to Sneeze At 2Health News:Health Fears Are Nothing to Sneeze At 3Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:Gilsbar is Sole Louisiana Company to Win National Award from the American Heart Association 2Health News:Top 10 Ways to Prevent or Delay Alzheimer's 2Health News:Federal Judge Rejects Tobacco Companies' Effort to Block Key Provisions of New Tobacco Regulation Law 2
(Date:9/17/2014)...  Lightbeam Health Solutions announced today an agreement ... ACO) to deploy the Lightbeam population health platform ... while reducing costs. Photo - ... Care Organization is the ACO operating entity of ... is to be the premier integrated health care ...
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... 6 Reportlinker.com announces that a new ... catalogue. , Reportlinker Adds Gilead ... http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html , Introduction , This ... for Gilead in the prescription pharmaceutical sector. ...
... Oct. 6 Centocor Ortho Biotech Inc. and Schering-Plough ... European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, ... arthritis (RA), active and progressive psoriatic arthritis (PsA) and ... the European Union, SIMPONI is approved as a 50 ...
Cached Medicine Technology:Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 2Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 3Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
The Auto Suture™ EEA™ reusable stainless steel sizer set has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... is synthesized in the parafollicular C-cells of ... secretory granules. The major action of calcitonin ... inhibiting osteoclast activity, resulting in decreased mobilization ... is most evident in conditions associated with ...
... The pHEM-ALERT® test provides a method for ... The pHEM-ALERT test is comprised of a plastic ... color chart and a package insert. The plastic ... flat key. pHEM-ALERT is indicated for measuring vaginal ...
Medicine Products: